Health

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (hereafter…

thaipr.net

11 ต.ค. 65

On World Mental Health Day, NCCN Announces Free Updated Distress Screening Tool, Available in More Than 70 Languages

The National Comprehensive Cancer Network’s Distress Thermometer helps people with cancer worldwide receive better care by empowering discussion and recommending best practices for managing psychological wellness. The National Comprehensive Cancer Network® (NCCN®) today announced an updated NCCN Distress Thermometer, available in more than 70 languages, to help people around the world identify and address psychosocial stressors that…

thaipr.net

10 ต.ค. 65

Mediterranean diet improves immunotherapy response rates and progression-free survival in advanced melanoma, new study presented at UEG Week suggests

Eating a Mediterranean diet, rich in fibre, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients, a new study presented today at UEG Week 2022 has found. Experts anticipate that the diet will play an important role in the success of immunotherapy and trials […]

thaipr.net

10 ต.ค. 65

TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

For people with early Alzheimer’s (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals For people with mild to moderate Alzheimer’s, HMTM stabilised cognition and function and reduced rate of brain atrophy compared to historical matched individuals with AD HMTM […]

thaipr.net

6 ต.ค. 65

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research   Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational…

thaipr.net

3 ต.ค. 65

ABILITY DIABETES GLOBAL – A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

ABILITY DIABETES-GLOBAL (ADG), is the World’s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting stent , Abluminus DES+ (Concept Medical Inc.) with the XIENCE family of DES (Abbott Cardiovascular). Diabetes has been the Achilles heel for any vascular interventional procedures and there is a clinical need for adequately […]

thaipr.net

30 ก.ย. 65

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) […]

thaipr.net

30 ก.ย. 65
1 … 57 58 59 60 61 … 128

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.